Nalaganje...
Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer
PURPOSE: Seviteronel (INO-464) is an oral, selective cytochrome P450c17a (CYP17) 17,20-lyase (lyase) and androgen receptor (AR) inhibitor with in vitro and in vivo anti-tumor activity. This open-label phase 1 clinical study evaluated safety, tolerability, pharmacokinetics (PK) and activity of once-d...
Shranjeno v:
| izdano v: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6226357/ https://ncbi.nlm.nih.gov/pubmed/29744674 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-018-4813-z |
| Oznake: |
Označite
Brez oznak, prvi označite!
|